WuXi Biologics (Cayman) Inc
HKEX:2269
WuXi Biologics (Cayman) Inc
HKEX:2269
Price:
34.42
HKD
-1.99%
Market Closed
Market Cap:
HK$142.4B
Income Statement
Earnings Waterfall
WuXi Biologics (Cayman) Inc
WuXi Biologics (Cayman) Inc
Income Statement
WuXi Biologics (Cayman) Inc
WuXi Biologics (Cayman) Inc
Currency: CNY
| Dec-2017 | Jun-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||
| Interest Expense |
36
|
0
|
0
|
5
|
20
|
37
|
34
|
28
|
29
|
31
|
54
|
110
|
148
|
137
|
147
|
168
|
|
| Revenue |
1 619
N/A
|
2 019
+25%
|
2 534
+26%
|
3 087
+22%
|
3 984
+29%
|
4 321
+8%
|
5 612
+30%
|
8 075
+44%
|
10 290
+27%
|
13 090
+27%
|
15 269
+17%
|
16 554
+8%
|
17 034
+3%
|
17 116
+0%
|
18 675
+9%
|
20 054
+7%
|
|
| Gross Profit | |||||||||||||||||
| Cost of Revenue |
(958)
|
(1 208)
|
(1 517)
|
(1 813)
|
(2 325)
|
(2 546)
|
(3 079)
|
(4 033)
|
(5 461)
|
(7 144)
|
(8 545)
|
(9 683)
|
(10 206)
|
(10 499)
|
(11 025)
|
(11 501)
|
|
| Gross Profit |
661
N/A
|
811
+23%
|
1 018
+25%
|
1 274
+25%
|
1 659
+30%
|
1 775
+7%
|
2 533
+43%
|
4 042
+60%
|
4 829
+19%
|
5 945
+23%
|
6 724
+13%
|
6 871
+2%
|
6 828
-1%
|
6 617
-3%
|
7 651
+16%
|
8 554
+12%
|
|
| Operating Income | |||||||||||||||||
| Operating Expenses |
(222)
|
(282)
|
(321)
|
(368)
|
(597)
|
(655)
|
(888)
|
(1 128)
|
(1 520)
|
(1 719)
|
(2 166)
|
(2 493)
|
(2 681)
|
(2 763)
|
(2 821)
|
(2 984)
|
|
| Selling, General & Administrative |
(175)
|
(214)
|
(270)
|
(344)
|
(451)
|
(523)
|
(727)
|
(1 015)
|
(1 157)
|
(1 274)
|
(1 691)
|
(1 950)
|
(2 109)
|
(2 379)
|
(2 299)
|
(2 298)
|
|
| Research & Development |
(74)
|
(94)
|
(169)
|
(222)
|
(260)
|
(275)
|
(304)
|
(295)
|
(502)
|
(657)
|
(683)
|
(753)
|
(786)
|
(788)
|
(766)
|
(766)
|
|
| Other Operating Expenses |
28
|
27
|
118
|
198
|
114
|
144
|
143
|
181
|
139
|
212
|
208
|
210
|
214
|
404
|
244
|
80
|
|
| Operating Income |
439
N/A
|
529
+21%
|
697
+32%
|
906
+30%
|
1 062
+17%
|
1 120
+5%
|
1 645
+47%
|
2 914
+77%
|
3 309
+14%
|
4 226
+28%
|
4 558
+8%
|
4 378
-4%
|
4 147
-5%
|
3 855
-7%
|
4 830
+25%
|
5 570
+15%
|
|
| Pre-Tax Income | |||||||||||||||||
| Interest Income Expense |
(119)
|
(37)
|
97
|
100
|
65
|
250
|
321
|
405
|
694
|
639
|
810
|
591
|
91
|
44
|
15
|
611
|
|
| Non-Reccuring Items |
(16)
|
(20)
|
(56)
|
(41)
|
0
|
(51)
|
0
|
0
|
0
|
0
|
0
|
(7)
|
(54)
|
(234)
|
0
|
(21)
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(10)
|
0
|
(10)
|
(5)
|
(11)
|
(11)
|
(11)
|
(5)
|
|
| Pre-Tax Income |
304
N/A
|
473
+56%
|
738
+56%
|
965
+31%
|
1 127
+17%
|
1 320
+17%
|
1 966
+49%
|
3 319
+69%
|
3 993
+20%
|
4 865
+22%
|
5 358
+10%
|
4 957
-7%
|
4 174
-16%
|
3 653
-12%
|
4 834
+32%
|
6 154
+27%
|
|
| Net Income | |||||||||||||||||
| Tax Provision |
(51)
|
(63)
|
(107)
|
(134)
|
(116)
|
(28)
|
(273)
|
(474)
|
(485)
|
(618)
|
(808)
|
(690)
|
(603)
|
(640)
|
(889)
|
(1 232)
|
|
| Income from Continuing Operations |
253
|
410
|
630
|
830
|
1 010
|
1 292
|
1 693
|
2 845
|
3 509
|
4 247
|
4 550
|
4 267
|
3 571
|
3 013
|
3 945
|
4 922
|
|
| Income to Minority Interest |
0
|
0
|
0
|
1
|
3
|
8
|
(4)
|
(50)
|
(120)
|
(166)
|
(130)
|
(115)
|
(171)
|
(381)
|
(589)
|
(725)
|
|
| Net Income (Common) |
253
N/A
|
410
+62%
|
631
+54%
|
831
+32%
|
1 014
+22%
|
1 300
+28%
|
1 689
+30%
|
2 795
+65%
|
3 388
+21%
|
4 081
+20%
|
4 420
+8%
|
4 152
-6%
|
3 400
-18%
|
2 632
-23%
|
3 356
+28%
|
4 196
+25%
|
|
| EPS (Diluted) |
0.07
N/A
|
0.1
+43%
|
0.16
+60%
|
0.21
+31%
|
0.25
+19%
|
0.32
+28%
|
0.4
+25%
|
0.64
+60%
|
0.77
+20%
|
0.93
+21%
|
1.01
+9%
|
0.95
-6%
|
0.78
-18%
|
0.61
-22%
|
0.78
+28%
|
0.99
+27%
|
|
Switch to:
Switch to:
See Also
Discover More
